Keyphrases
Unplanned Readmission
33%
Cancer Patients
33%
Cancer Hospital
33%
Tumor
33%
Preventability
33%
Readmission Rates
33%
Fusion Protein
33%
Comprehensive Cancer Center
33%
Potentially Preventable
33%
Targeted Therapy
33%
COVID-19
33%
Neurotrophic Tyrosine Kinase Receptor
33%
7-day Readmission
33%
Hospital Medicine
33%
Tropomyosin Receptor Kinase B
33%
Medical Oncology
33%
Kinase Fusion
33%
Emergency Department
33%
Cancer Types
21%
Goals of Care Conversations
21%
Chromosomal Rearrangements
20%
GI Malignancy
16%
MD Anderson Cancer Center
16%
Retrospective Analysis
16%
Most Common Form
16%
Care Delivery
16%
Premature Discharge
16%
Readmission
16%
Oncology Patients
16%
Statistical Analysis
16%
Readmission Risk
16%
Most Cited
16%
Kinase Inhibitor
13%
Malignancy
13%
Hematological Malignancies
11%
Survival Outcomes
9%
Dyspnea
9%
Solid Malignancies
6%
Cell Survival
6%
Receptor Antagonist
6%
Oncogenesis
6%
System Function
6%
Central Nervous System Development
6%
Druggability
6%
Entrectinib
6%
Fusion Kinase
6%
Promoting Role
6%
Ongoing Clinical Trials
6%
Clinical Trials
6%
Antitumor Activity
6%
Medicine and Dentistry
Hospitalist
33%
Oncology
33%
Receptor Tyrosine Kinase
33%
Chimeric Protein
33%
Targeted Therapy
33%
Phosphotransferase
33%
Pneumonia
33%
Immune Checkpoint Inhibitor
33%
Tropomyosin
33%
Neoplasm
33%
Cancer
20%
Receptor
13%
Clinical Trial
13%
Phosphotransferase Inhibitor
13%
Stage 4 Cancer
11%
Immune-Related Adverse Events
7%
Cell Proliferation
6%
Gene Fusion
6%
Carcinogenesis
6%
Entrectinib
6%
Peripheral Nervous System
6%
Central Nervous System
6%
Multigene Family
6%
Cell Survival
6%
Oncogene
6%
Neurogenesis
6%
Nervous System Function
6%
Larotrectinib
6%
Antineoplastic Activity
6%
Respiratory Medicine
5%
Lung Cancer
5%
Clinician
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Receptor
33%
Chimeric Protein
33%
Phosphotransferase
33%
Neoplasm
33%
Diseases
30%
Coronavirinae
22%
Tropomyosin
18%
Prematurity
8%
Infection
7%
Hematologic Malignancy
7%
Solid Malignant Neoplasm
7%
Phosphotransferase Inhibitor
7%
Clinical Trial
7%
Dyspnea
7%
